Similar articles

• Re: National Prostate Cancer Screening Rates after the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening.

  Taneja SS. Taneja SS. J Urol. 2016 Feb;195(2):350-1. doi: 10.1016/j.juro.2015.10.166. Epub 2015 Nov 4. J Urol. 2016. PMID: 26852972 No abstract available.
• Re: Changes in Prostate-specific Antigen Testing Relative to the Revised US Preventive Services Task Force Recommendation on Prostate Cancer Screening.

  Fleshner K, Carlsson SV. Fleshner K, et al. Eur Urol. 2022 Mar;81(3):313. doi: 10.1016/j.eururo.2021.12.028. Epub 2022 Jan 10. Eur Urol. 2022. PMID: 35027257 No abstract available.
• Re: Prostate Cancer Incidence 5 Years After US Preventive Services Task Force Recommendations Against Screening.

  Lehrer S, Rheinstein PH. Lehrer S, et al. J Natl Cancer Inst. 2020 Oct 1;112(10):1067-1068. doi: 10.1093/jnci/djaa092. J Natl Cancer Inst. 2020. PMID: 32602898 Free PMC article. No abstract available.
• Impact of the United States Preventive Services Task Force 'D' recommendation on prostate cancer screening and staging.

  Eapen RS, Herlemann A, Washington SL 3rd, Cooperberg MR. Eapen RS, et al. Curr Opin Urol. 2017 May;27(3):205-209. doi: 10.1097/MOU.0000000000000383. Curr Opin Urol. 2017. PMID: 28221220 Review.
• Prostate Cancer Screening and the Associated Controversy.

  Tabayoyong W, Abouassaly R. Tabayoyong W, et al. Surg Clin North Am. 2015 Oct;95(5):1023-39. doi: 10.1016/j.suc.2015.05.001. Epub 2015 Jun 23. Surg Clin North Am. 2015. PMID: 26315521 Review.